Metastatic Melanoma Clinical Trial Results | OPDIVO® (nivolumab)
Melanoma Adjuvant Clinical Trial Results | OPDIVO® (nivolumab)
Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post
Long-term Analysis Shows Nivolumab Bests Ipilimumab in Resected
Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma | ESMO
Adjuvant Nivolumab Continues to Provide Superior Recurrence-Free
Dual checkpoint blockade improves PFS as first-line treatment of advanced melanoma
Nivolumab Combined with Ipilimumab
Nivolumab: targeting PD-1 to bolster antitumor immunity | Future Oncology
Phase II trials - Ultimovacs
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma | Nature Medicine
BMS' Opdivo/Yervoy improves long-term survival for melanoma patients - PharmaTimes
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
Nivolumab plus ipilimumab benefits patients with asymptomatic melanoma brain metastases
Melanoma Adjuvant Clinical Trial Results | OPDIVO® (nivolumab)
Melanoma Adjuvant Clinical Trial Results | OPDIVO® (nivolumab)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Metastatic Melanoma Clinical Trial Results | OPDIVO® (nivolumab)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Nivolumab (Opdivo) Drug Information
Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider
Nivolumab and Relatlimab for Advanced Melanoma - NCI
